Literature DB >> 9349501

Chimeric MLL products with a Ras binding cytoplasmic protein AF6 involved in t(6;11) (q27;q23) leukemia localize in the nucleus.

T Joh1, K Yamamoto, Y Kagami, H Kakuda, T Sato, T Yamamoto, T Takahashi, R Ueda, K Kaibuchi, M Seto.   

Abstract

In infantile leukemias and therapy-related leukemias, the MLL gene is frequently found to be disrupted and fused to various translocation partner genes, such as AF4/FEL, LTG9/AF9 and LTG19/ENL as a result of 11q23 translocations. We previously showed that the N-terminal portion common to various chimeric MLL products, as well as to MLL-LTG9 and MLL-LTG19, localizes in the nuclei, and therefore suggested that it might play an important role in leukemogenesis. In the present study, MLL-AF6 chimeric products found in the t(6;11)(q27;q23) translocation were analysed since AF6, a Ras-binding protein, exhibits a different subcellular localization from that of LTG9/AF9 and LTG19/ENL. Immunofluorescence staining data and cell fractionation analyses demonstrated that MLL-AF6 chimeric products localize in the nuclei despite the fact that AF6 itself localizes in the cytoplasm, confirming the importance of the nuclear localization of chimeric MLL products. The region in the N-terminal portion of MLL responsible for this nuclear localization was examined and found to be a region containing AT-hook motifs.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9349501     DOI: 10.1038/sj.onc.1201332

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  9 in total

1.  MSF (MLL septin-like fusion), a fusion partner gene of MLL, in a therapy-related acute myeloid leukemia with a t(11;17)(q23;q25).

Authors:  M Osaka; J D Rowley; N J Zeleznik-Le
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-25       Impact factor: 11.205

2.  The human formin-binding protein 17 (FBP17) interacts with sorting nexin, SNX2, and is an MLL-fusion partner in acute myelogeneous leukemia.

Authors:  U Fuchs; G Rehkamp; O A Haas; R Slany; M Kōnig; S Bojesen; R M Bohle; C Damm-Welk; W D Ludwig; J Harbott; A Borkhardt
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-03       Impact factor: 11.205

3.  The amino terminus targets the mixed lineage leukemia (MLL) protein to the nucleolus, nuclear matrix and mitotic chromosomal scaffolds.

Authors:  C Caslini; A S Alarcòn; J L Hess; R Tanaka; K G Murti; A Biondi
Journal:  Leukemia       Date:  2000-11       Impact factor: 11.528

Review 4.  Molecular pathogenesis of MLL-associated leukemias.

Authors:  Mariko Eguchi; Minenori Eguchi-Ishimae; Mel Greaves
Journal:  Int J Hematol       Date:  2005-07       Impact factor: 2.490

Review 5.  The role of the MLL gene in infant leukemia.

Authors:  Mariko Eguchi; Minenori Eguchi-Ishimae; Mel Greaves
Journal:  Int J Hematol       Date:  2003-12       Impact factor: 2.490

Review 6.  The robotic mouse: unravelling the function of AF4 in the cerebellum.

Authors:  Emmanuelle Bitoun; Kay Elizabeth Davies
Journal:  Cerebellum       Date:  2005       Impact factor: 3.648

7.  Evolution of AF6-RAS association and its implications in mixed-lineage leukemia.

Authors:  Matthew J Smith; Elizabeth Ottoni; Noboru Ishiyama; Marilyn Goudreault; André Haman; Claus Meyer; Monika Tucholska; Genevieve Gasmi-Seabrook; Serena Menezes; Rob C Laister; Mark D Minden; Rolf Marschalek; Anne-Claude Gingras; Trang Hoang; Mitsuhiko Ikura
Journal:  Nat Commun       Date:  2017-10-23       Impact factor: 14.919

8.  Membrane tension sensing molecule-FNBP1 is a prognostic biomarker related to immune infiltration in BRCA, LUAD and STAD.

Authors:  Zixuan Wang; Zixin Tian; Xi Song; Jun Zhang
Journal:  BMC Immunol       Date:  2022-01-08       Impact factor: 3.615

9.  Afadin couples RAS GTPases to the polarity rheostat Scribble.

Authors:  Marilyn Goudreault; Valérie Gagné; Chang Hwa Jo; Swati Singh; Ryan C Killoran; Anne-Claude Gingras; Matthew J Smith
Journal:  Nat Commun       Date:  2022-08-05       Impact factor: 17.694

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.